Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

6 Months Ended

Jan. 31, 2023

Three months ended January 31, 2023	Clinical Services			Products			Other			Consolidated
Revenues	$	8,824		$	7,514			—		$	16,338

Operating costs and expenses:
Cost of revenues		10,463			4,616			—			15,079
Research and development		306			1,113			12			1,431
Selling, general and administrative		6,943			2,556			2,313			11,812
Legal fee expense		107			11			877			995
Total operating costs and expenses		17,819			8,296			3,202			29,317

Operating loss		(8,995	)		(782	)		(3,202	)		(12,979	)

Other income (expense):
Interest, net		(1	)		29			34			62
Other		7			2			116			125
Foreign exchange loss		—			1,472			—			1,472
(Loss) income before income taxes	$	(8,989	)	$	721		$	(3,052	)	$	(11,320	)

Depreciation and amortization included above	$	386			171			91			648

Share-based compensation included in above:
Selling, general and administrative		65			20			409			494
Cost of revenues		15			6			—			21
Total	$	80			26			409			515

Capital expenditures	$	196			632			41			869

Three months ended January 31, 2022	Clinical Services			Products			Other			Consolidated
Revenues	$	23,674		$	10,372			—		$	34,046

Operating costs and expenses:
Cost of revenues		12,586			5,252			—			17,838
Research and development		89			711			20			820
Selling, general and administrative		6,811			3,039			4,616			14,466
Legal fee expense		148			—			2,697			2,845
Total operating costs and expenses		19,634			9,002			7,333			35,969

Operating income (loss)		4,040			1,370			(7,333	)		(1,923	)

Other income (expense):
Interest, net		(3	)		9			62			68
Other		5			3			(358	)		(350	)
Foreign exchange loss		—			(450	)		—			(450	)
Income (loss) before income taxes	$	4,042		$	932		$	(7,629	)	$	(2,655	)

Depreciation and amortization included above	$	438			190			77			705

Share-based compensation included in above:
Selling, general and administrative		16			1			650			667
Cost of revenues		12			—			—			12
Total	$	28			1			650			679

Capital expenditures	$	283			730			201			1,214

Six months ended January 31, 2023	Clinical Services			Products			Other			Consolidated
Revenues	$	19,997		$	14,617			—		$	34,614

Operating costs and expenses:
Cost of revenues		20,545			9,205			—			29,750
Research and development		603			1,803			21			2,427
Selling, general and administrative		13,493			4,986			4,784			23,263
Legal fee expense		171			36			1,859			2,066
Total operating costs and expenses		34,812			16,030			6,664			57,506

Operating loss		(14,815	)		(1,413	)		(6,664	)		(22,892	)

Other income (expense):
Interest, net		(3	)		54			81			132
Other		12			4			114			130
Foreign exchange loss		—			675			—			675
Loss before income taxes	$	(14,806	)	$	(680	)	$	(6,469	)	$	(21,955	)

Depreciation and amortization included above	$	918			336			174			1,428

Share-based compensation included in above:
Selling, general and administrative		114			40			749			903
Cost of revenues		31			11			—			42
Total	$	145			51			749			945

Capital expenditures	$	359			938			224			1,521

Six months ended January 31, 2022	Clinical Services			Products			Other			Consolidated
Revenues	$	43,415		$	17,150			—		$	60,565

Operating costs and expenses:
Cost of revenues		23,789			9,322			—			33,111
Research and development		96			1,443			25			1,564
Selling, general and administrative		12,812			6,134			6,572			25,518
Legal fee expense		205			13			3,909			4,127
Total operating costs and expenses		36,902			16,912			10,506			64,320

Operating income (loss)		6,513			238			(10,506	)		(3,755	)

Other income (expense):
Interest, net		(5	)		18			94			107
Other		54			5			(554	)		(495	)
Foreign exchange loss					(831	)		—			(831	)
Income (loss) before income taxes	$	6,562		$	(570	)	$	(10,966	)	$	(4,974	)

Depreciation and amortization included above	$	856			402			148			1,406

Share-based compensation included in above:
Selling, general and administrative		36			1			842			879
Cost of revenues		16			—			—			16
Total	$	52			1			842			895

Capital expenditures	$	593			1,216			438			2,247